IP Library Granted Patent US 9,404,079
Granted Patent B2
US 9,404,079 · App. 13/909,128 · Granted Aug 2, 2016

Media for culturing stem cells

Inventors: Michal Amit (Misgav, IL); Joseph Itskovitz-Eldor (Haifa, IL)
Assignee: Technion Research & Development Foundation Limited
C12N5/0606C12N5/0037C12N5/0043C12N5/0056C12N5/0603C12N2500/90C12N2500/98C12N2501/115C12N2501/15C12N2501/23C12N2533/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,404,079
App. No.
13/909,128
Granted
Aug 2, 2016
Kind
B2
Abstract

Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of mainataining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.

Claims (13)

1. A method of expanding and maintaining human pluripotent stem cells in an undifferentiated state, the method comprising culturing the human pluripotent stem cells in a culture medium comprising a transforming growth factor beta 3 (TGFβ3) isoform— and factors that maintain and expand human pluripotent stem cells in an undifferentiated state, thereby expanding and maintaining the human pluripotent stem cells in the undifferentiated state.

2. The method of claim 1 , wherein said human pluripotent stem cells are human embryonic stem cells.

3. The method of claim 1 , wherein the human pluripotent stem cells are cultured in suspension.

4. The method of claim 1 , wherein the human pluripotent stem cells are cultured on a feeder-layer free matrix.

5. The method of claim 4 , wherein said feeder-layer free matrix is a fibronectin matrix.

6. The method of claim 1 , wherein the human pluripotent stem cells are cultured on feeder cells.

7. The method of claim 1 , wherein said TGFβ3 isoform is provided at a concentration of at least 0.5 ng/ml.

8. The method of claim 1 , wherein said TGFβ3 isoform is provided at a concentration of at least 2 ng/ml.

9. The method of claim 1 , wherein said culture medium further comprises basic fibroblast growth factor (bFGF).

10. The method of claim 9 , wherein said bFGF is provided at a concentration of at least 2 ng/ml.

11. The method of claim 1 , wherein said culture medium is serum-free.

12. The method of claim 1 , wherein said culture medium is devoid of animal contaminant.

13. The method of claim 3 , wherein said suspension is protein carrier-free.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2013
From: AMIT, MICHAL; ITSKOVITZ-ELDOR, JOSEPH
To: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
Reel/Frame 030746/0703 →
Continuity (4)
Division 11991077
Provisional Application 60711668 · Aug 29, 2005
Provisional Application 60834795 · Aug 2, 2006
Related Publication 20130252329A1 · Sep 26, 2013